The systemic treatment of advanced and metastatic bladder cancer.
about
A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer.Decreased risk of bladder cancer in men treated with quinazoline-based α1-adrenoceptor antagonists.Upregulated UHRF1 promotes bladder cancer cell invasion by epigenetic silencing of KiSS1.Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer.Role of systemic peri-operative chemotherapy in management of transitional cell carcinoma of bladder.Treatment of invasive bladder cancer: lessons from the past and perspective for the future.A study of split-dose cisplatin-based neo-adjuvant chemotherapy in muscle-invasive bladder cancer.Denosumab: a new option in the treatment of bone metastases from urological cancersAntisense oligodeoxynucleotide therapy for bladder cancer: recent advances and future prospects.Recent advances in the treatment of bladder cancer.Metabolism and transport of oxazaphosphorines and the clinical implications.Suppressions of Migration and Invasion by Cantharidin in TSGH-8301 Human Bladder Carcinoma Cells through the Inhibitions of Matrix Metalloproteinase-2/-9 Signaling.A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo.Phase I/II study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours.Adjuvant androgen deprivation therapy augments cure and long-term cancer control in men with poor prognosis, nonmetastatic prostate cancer.Outcome following radical cystectomy and bladder-preservation therapy in patients with invasive carcinoma of urinary bladder.Management of metastatic urothelial cancer: the role of surgery as an adjunct to chemotherapyComparing how significantly the pharmacological treatment of genitourinary cancer in a non-curative setting affects endpoints of survival or response.MiR-124 exerts tumor suppressive functions on the cell proliferation, motility and angiogenesis of bladder cancer by fine-tuning UHRF1.Biodistribution and safety assessment of bladder cancer specific recombinant oncolytic adenovirus in subcutaneous xenografts tumor model in nude mice.Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126Twist1 and Y-box-binding protein-1 promote malignant potential in bladder cancer cells.Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine.miR-128 downregulation promotes growth and metastasis of bladder cancer cells and involves VEGF-C upregulation.Weekly regimen of epirubicin and paclitaxel as second-line chemotherapy in patients with metastatic transitional cell carcinoma of urothelial tract: results of a phase II study.A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102.A Comprehensive Review of US FDA-Approved Immune Checkpoint Inhibitors in Urothelial Carcinoma.Pegylated liposomal doxorubicin as third-line chemotherapy in patients with metastatic transitional cell carcinoma of urothelial tract: results of a phase II study.Transitional cell carcinoma of the ovary.
P2860
Q33361999-F8A9570C-D57D-479D-AE39-DBAFBB9482D2Q34066067-62D5BE8B-C74C-4757-8EA8-274873C4BC89Q34278046-A6D91490-D367-44B8-B87D-3F16C0E8A20FQ34826155-684DBD51-0159-4ECA-8226-213DFC16C101Q35125750-E74CBCE4-BA8A-478C-9332-404AB46D6B1FQ35873130-9BC6A7C5-E483-4C67-9B7E-4E59C490A038Q35995341-71D09087-89A0-4030-B635-4FA84E209AEEQ36277837-B3CE9999-EE50-4CBF-B20C-2260ABF7F7E7Q36334885-348FB67F-D519-452B-8649-26B4E2D86A17Q36334892-E8FAD34D-E451-4258-A835-5F705ABD953DQ36360811-8004E3C8-74E4-4A66-B05C-57B9D1717CC8Q36599990-241C0611-342A-4F52-8E15-09FB39347EE2Q36612034-A04EA449-DAFF-484D-9038-2E01D05EA77DQ36696098-D5FCCFF3-4746-4B1F-93BC-A5E9E64014A7Q36868487-C645D0D1-2F60-490A-AAFA-9807A6D78793Q37197518-C2CC7593-BDAF-4E2A-8843-D9D5EC44848BQ37658359-6034C397-FB68-4890-9EE3-86FE62E0E9AAQ37959798-5135111C-55CF-4D16-BB51-EE2D286192E4Q38840573-321B4507-AA3B-4B03-AFCF-378AFC4F3EBFQ39386829-4958717A-3259-4486-9051-26AEDE469753Q39457478-20D5109A-32B4-437B-B9BF-22C8FECDB232Q39630735-2BF3D6EB-FD00-4F56-BD1D-8E55D78FC77CQ43136603-45F454DA-252F-46BC-B8E3-D8E5C3E96CA2Q43148069-EC549409-ED2B-4E4D-8148-169802281AACQ43654255-45FC5725-2EA2-474A-BB5A-BCD89FE92606Q46961027-AD9C421A-08B5-4D99-A3E7-B388D9881F66Q48154177-D037C76F-E4E7-4DE0-8A1C-5173090E265BQ50795929-683BE5D7-569F-42A4-80D3-F210752B3476Q53650878-F310A74E-6EE3-4DC7-9944-C3445375D879
P2860
The systemic treatment of advanced and metastatic bladder cancer.
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The systemic treatment of advanced and metastatic bladder cancer.
@ast
The systemic treatment of advanced and metastatic bladder cancer.
@en
type
label
The systemic treatment of advanced and metastatic bladder cancer.
@ast
The systemic treatment of advanced and metastatic bladder cancer.
@en
prefLabel
The systemic treatment of advanced and metastatic bladder cancer.
@ast
The systemic treatment of advanced and metastatic bladder cancer.
@en
P1433
P1476
The systemic treatment of advanced and metastatic bladder cancer
@en
P2093
Nicholas D James
P304
P356
10.1016/S1470-2045(03)01168-9
P577
2003-08-01T00:00:00Z